AbbVie
$262.82Change from previous close: +1.11%Absolute change: +$2.89
At a glance
- Revenue growth
- +8.57%
- 2025 vs 2024
- Net income growth
- −1.22%
- 2025 vs 2024
- Net margin
- 6.9%
- 2024: 7.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3,436 | 3,829 | 5,218 | 7,024 | 5,153 | 1,635 | 7,048 | 5,447 | 2,271 | 4,040 | 4,753 | 7,574 |
| Depreciation and amortization | 1,883 | 1,936 | 1,987 | 2,063 | 2,050 | 2,039 | 2,102 | 2,079 | 2,131 | 2,074 | 2,076 | 2,235 |
| Capital expenditure | -322 | -265 | -329 | -381 | -269 | -235 | -291 | -249 | -241 | -193 | -205 | -219 |
| Investing cash flow | -1,197 | -574 | -1,463 | -3,264 | -1,181 | -735 | -1,874 | -8,256 | -1,102 | -9,588 | -800 | -369 |
| Financing cash flow | -5,054 | 919 | -4,166 | -4,590 | -2,710 | -1,258 | -6,861 | -3,072 | -6,097 | 10,819 | -4,449 | -2,661 |
| Dividends paid | -3,070 | -3,086 | -2,911 | -2,911 | -2,910 | -2,925 | -2,752 | -2,751 | -2,750 | -2,772 | -2,626 | -2,627 |
| Share repurchases | -9.0 | -1,489 | -3.0 | -4.0 | -12.0 | -961 | -358 | -17.0 | -9.0 | -1,324 | -3.0 | -4.0 |
| Debt issued | 0.0 | 7,991 | -500 | 241 | 3,963 | 5,587 | 2,000 | 0.0 | 0.0 | 19,971 | — | — |
| Debt repaid | -2,000 | -2,499 | -799 | -2,016 | -3,754 | -3,026 | -5,762 | -403 | -3,348 | -5,108 | -1,794 | -2.0 |
| Effect of exchange rates | -7.0 | -12.0 | 11.0 | -8.0 | 30.0 | 9.0 | -46.0 | 8.0 | -9.0 | -18.0 | 23.0 | -16.0 |
| Net change in cash | -2,822 | 4,162 | -400 | -838 | 1,292 | -349 | -1,733 | -5,873 | -4,937 | 5,253 | -473 | 4,528 |
| Free cash flow | 3,114 | 3,564 | 4,889 | 6,643 | 4,884 | 1,400 | 6,757 | 5,198 | 2,030 | 3,847 | 4,548 | 7,355 |
| Levered free cash flow | 2,082 | 3,590 | 4,969 | 6,229 | 6,023 | 1,116 | 6,862 | 5,470 | 2,925 | 4,152 | 5,016 | 7,430 |